Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy - PubMed (original) (raw)
Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy
Alicia J Jenkins et al. Kidney Int. 2003 Sep.
Free article
Abstract
Background: Lipoproteins may contribute to diabetic nephropathy. Nuclear magnetic resonance (NMR) can quantify subclasses and mean particle size of very low density lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein (HDL), and LDL particle concentration. The relationship between detailed lipoprotein analyses and diabetic nephropathy is of interest.
Methods: In a cross-sectional study, lipoproteins from 428 women and 540 men from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort were characterized by conventional lipid enzymology, NMR, apolipoprotein levels, and LDL oxidizibility. Linear regression was performed for each lipoprotein parameter versus log albumin excretion rate (AER), with and without covariates for age, diabetes duration, HbA1c, hypertension, body mass index, waist-hip ratio, and DCCT treatment group. Significance was taken at P < 0.05.
Results: By multivariate analysis, conventional profile, total triglycerides, total- and LDL cholesterol, but not HDL cholesterol, were associated with AER. NMR-determined large, medium, and small VLDL were associated with AER in both genders (except large VLDL in women), and intermediate density lipoprotein (IDL) was associated with AER (men only). LDL particle concentration and ApoB were positively associated with AER (in men and in the total cohort), and there was a borderline inverse association between LDL diameter and AER in men. Small HDL was positively associated with AER and a borderline negative association was found for large HDL. No associations were found with ApoA1, Lp(a), or LDL oxidizibility.
Conclusion: Potentially atherogenic lipoprotein profiles are associated with renal dysfunction in type 1 diabetes and further details are gained from NMR analysis. Longitudinal studies are needed to determine if dyslipoproteinemia can predict patients at risk of nephropathy, or if lipoprotein-related interventions retard nephropathy.
Similar articles
- Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort.
Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, Klein RL. Lyons TJ, et al. Invest Ophthalmol Vis Sci. 2004 Mar;45(3):910-8. doi: 10.1167/iovs.02-0648. Invest Ophthalmol Vis Sci. 2004. PMID: 14985310 - Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness.
Lyons TJ, Jenkins AJ, Zheng D, Klein RL, Otvos JD, Yu Y, Lackland DT, McGee D, McHenry MB, Lopes-Virella M, Garvey WT; DCCT/EDIC Research Group. Lyons TJ, et al. Diabet Med. 2006 Sep;23(9):955-66. doi: 10.1111/j.1464-5491.2006.01905.x. Diabet Med. 2006. PMID: 16922701 - Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia.
Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL; DCC/EDIC Research Group. Jenkins AJ, et al. Diabetes Care. 2003 Mar;26(3):810-8. doi: 10.2337/diacare.26.3.810. Diabetes Care. 2003. PMID: 12610042 - Atherogenic lipoproteins in end-stage renal disease.
Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y. Shoji T, et al. Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S30-3. doi: 10.1053/ajkd.2001.27393. Am J Kidney Dis. 2001. PMID: 11576918 Review. - Lipoprotein abnormalities in diabetic nephropathy.
Hirano T. Hirano T. Kidney Int Suppl. 1999 Jul;71:S22-4. doi: 10.1046/j.1523-1755.1999.07106.x. Kidney Int Suppl. 1999. PMID: 10412730 Review.
Cited by
- Development and external validation of a machine learning model to predict diabetic nephropathy in T1DM patients in the real-world.
Du Z, Liu X, Li J, Min H, Ma Y, Hua W, Zhang L, Zhang Y, Shang M, Chen H, Yin H, Tian L. Du Z, et al. Acta Diabetol. 2024 Nov 11. doi: 10.1007/s00592-024-02404-z. Online ahead of print. Acta Diabetol. 2024. PMID: 39527297 - Microalbuminuria and lipid variations in adolescents diagnosed with type 1 diabetes.
Mohammedsaeed W, Binjawhar DN. Mohammedsaeed W, et al. Heliyon. 2024 Jun 12;10(12):e32824. doi: 10.1016/j.heliyon.2024.e32824. eCollection 2024 Jun 30. Heliyon. 2024. PMID: 38994071 Free PMC article. - Lipoprotein (a) as a predictor of diabetic retinopathy in patients with type 2 diabetes: A systematic review.
Gholami Chahkand MS, Esmaeilpour Moallem F, Qezelgachi A, Seifouri K, Pesaran Afsharian A, Sheikhzadeh F, Poursalehi A, Fani Sadrabadi FS, Saghab Torbati M, Ramezanzade M, Alishiri G, Ansari A, Zare Dehabadi E, Karimi Matloub S, Sheikh Z, Deravi N, Mehrtabar S, Chichagi F, Faal Hamedanchi N, Arzaghi M, Asadi M, Alsadat Dadkhah P, Ansari A. Gholami Chahkand MS, et al. Diab Vasc Dis Res. 2023 Nov-Dec;20(6):14791641231197114. doi: 10.1177/14791641231197114. Diab Vasc Dis Res. 2023. PMID: 38018132 Free PMC article. Review. - Medication profiling in women with type 1 diabetes highlights the importance of adequate, guideline-based treatment in low-risk groups.
Lithovius R, Mutter S, Parente EB, Mäkinen VP, Valo E, Harjutsalo V, Groop PH. Lithovius R, et al. Sci Rep. 2023 Oct 19;13(1):17893. doi: 10.1038/s41598-023-44695-2. Sci Rep. 2023. PMID: 37857707 Free PMC article. - Triglyceride content of lipoprotein subclasses and kidney hemodynamic function and injury in adolescents with type 1 diabetes.
Pauley ME, Vinovskis C, MacDonald A, Baca M, Pyle L, Wadwa RP, Fornoni A, Nadeau KJ, Pavkov M, Nelson RG, Gordin D, de Boer IH, Tommerdahl KL, Bjornstad P. Pauley ME, et al. J Diabetes Complications. 2023 Feb;37(2):108384. doi: 10.1016/j.jdiacomp.2022.108384. Epub 2022 Dec 13. J Diabetes Complications. 2023. PMID: 36623423 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous